Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study by Bringhen, S. et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:






(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript






This is an author version of the following contribution: 
Questa è la versione dell’autore dell’opera:  
 
 
Bringhen, S., Mina, R., Cafro, A.M., Liberati, A.M., Spada, S., Belotti, A., Gaidano, G., Patriarca, F., 
Troia, R., Fanin, R., De Paoli, L., Rossi, G., Lombardo, A., Bertazzoni, P., Palumbo, A., Sonneveld, 
P., Boccadoro, M. 
 
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for 
relapsed/refractory myeloma: a phase I/II study 




The definitive version is available at:  







Once-weekly carfilzomib, pomalidomide and low-dose dexamethasone for 
relapsed/refractory myeloma: a phase I/II study 
 
Running head: Once-weekly KPd for Relapsed/Refractory Myeloma 
 
 
Sara Bringhen1, Roberto Mina1, Anna Maria Cafro2, Anna Marina Liberati3, Stefano Spada1, 
Angelo Belotti4, Gianluca Gaidano5, Francesca Patriarca6, Rossella Troia1, Renato Fanin6, 
Lorenzo De Paoli5, Giuseppe Rossi4, Alessandra Lombardo7, Paola Bertazzoni2, Antonio 
Palumbo1*, Pieter Sonneveld8, and Mario Boccadoro1 
 
 
1 Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e 
della Scienza di Torino, Torino, Italy; 2 Ospedale Niguarda Ca' Granda, Milan, Italy; 3 Università degli Studi di 
Perugia, Struttura Complessa Universitaria Oncoematologia - Azienda Ospedaliera Santa Maria di Terni, Terni, 
Italy; 4 SC Ematologia e Dipartimento di Oncologia Clinica, A.O. Spedali Civili, Brescia, Italy; 5 Division of 
Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; 6 Clinica 
Ematologica, Azienda sanitaria Universitaria Integrata, DAMe, Università di Udine, Udine , Italy; 7 Struttura 
Complessa Universitaria Oncoematologia - Azienda Ospedaliera Santa Maria di Terni, Terni, Italy; 8 Department of 




Corresponding author: Sara Bringhen, Myeloma Unit, Division of Hematology, University of 
Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Via 













 Despite the progress made in the past two decades, multiple myeloma (MM) remains an 
incurable disease and the prognosis of patients relapsing after first-generation novel agents is 
extremely poor (1). Pomalidomide and carfilzomib, respectively second-generation 
immunomodulatory drug (IMiD) and proteasome inhibitor (PI), proved to be effective in 
patients previously exposed to both lenalidomide and bortezomib(2–4) and received 
approval for the treatment of relapsed/refractory MM (RRMM).  
Synergism between IMiDs and PIs has been demonstrated (5–7): twice-weekly carfilzomib in 
combination with pomalidomide and dexamethasone (KPd) was well tolerated and effective 
in patients refractory to lenalidomide (8). 
Currently, carfilzomib is approved with the twice-weekly schedule at a dose of 27 mg/m2; 
however, higher doses of weekly carfilzomib, up to 70 mg/m2, could be safely administered, 
with similar efficacy as compared to the twice-weekly schedule [11-12]. 
Herein, we report the results of a phase I/II trial with once-weekly KPd (wKPd) in RRMM 
patients.  
Patient eligibility, study design and statistical analysis are summarized in Supplementary 
Appendix. 
Briefly, patients with relapsed MM, or RRMM to the last line of therapy, who received 1 to 3 
previous anti-myeloma therapies, and were primary refractory or relapsed and refractory to 
lenalidomide were eligible. Patients could be either pre-treated with bortezomib or 
bortezomib-naïve.  
In the phase 1 portion, the primary endpoint was the maximum tolerated dose (MTD) of 
wKPd (Table S1).  
In the phase 2 portion, patients received the MTD of carfilzomib; the primary endpoint was 
the partial response (PR) rate.  
Treatment with wKPD consisted of a fixed induction (eight 28-day cycles) with weekly 
carfilzomib (20 mg/m2 intravenously on day 1 cycle 1, then at a higher dose according to 
cohort level on days 8 and 15), pomalidomide (4 mg orally on days 1-21) and dexamethasone 
(20 mg on days 1, 8, 15 and 22; Figure S1). Afterwards, patients could receive maintenance 
treatment (28-day cycles) with carfilzomib (according to the assigned dose level, on days 1, 8 
and 15), pomalidomide (4 mg, on days 1-21/28) and dexamethasone (20 mg on days 1, 8, 15 
and 22), until progression or intolerance. According to physician’s discretion, patients could 
proceed to wKPd until progression or to maintenance with pomalidomide alone. Adverse 
event (AE) assessment and response criteria are described in Supplementary Appendix.  
The institutional review board at each participating centre approved the study in accordance 
with the Declaration of Helsinki. All patients provided written informed consent.  
Between July 2014 and December 2015, 57 patients were enrolled at 6 Italian centres: 15 
patients in the phase 1, 42 in the phase 2. Patient characteristics are listed in Table S2, dose 
levels and the observed DLTs are in Table S3.  
Five DLTs were observed: 2 with carfilzomib at the dose of 45 mg/ m2 (1 grade 3 
hypertension and 1 sudden death) and 3 with carfilzomib at the dose of 36 mg/ m2 (1 grade 3 
atrial fibrillation, 1 grade 3 hypertension and 1 grade 5 heart failure). Four of 5 DLTs  in the 
first 9 patients were considered related to hypertension.  
In light of the cardiovascular events observed, the safety committee established new safety 
procedures for both screening and treatment: all patients underwent a cardiovascular 
screening before starting treatment, and a strict blood-pressure control before and after 
carfilzomib infusion. 
As per protocol, 6 additional patients were enrolled at dose level -1 (carfilzomib 27 mg/ m2) 
and no DLTs were reported. The MTD of carfilzomib in combination with pomalidomide and 




Forty-eight patients were assigned to the MTD of carfilzomib; 47 of them were evaluable for 
safety and efficacy, 1 patient did not start treatment due to a protocol violation and, 
consequently, was not included in the analysis. 
Twenty-five (53%) patients completed the induction phase and proceeded to maintenance, 
while 22 patients discontinued treatment before maintenance: 17 (36%) due to progressive 
disease (PD), 2 (4%) for toxicity, 2 (4%) to proceed to allogeneic stem-cell transplantation 
and 1 (2%) for other reasons. 
Patients received a median of 8 cycles (range, 1-21 cycles) of study treatment. The overall 
response rate (ORR) reported after induction in patients treated at the MTD of carfilzomib 
was 62% (Table S4); 18 patients achieved PR (38%), 9 very good partial response (VGPR; 
19%), 1 near complete response (nCR; 2%) and 1 complete response (CR; 2%). Taking into 
account 11 patients who had a stable disease (23%), the clinical benefit rate was 85%.  
Responses were rapid, with median time to PR of 2.1 months (95% CI, 1.9 – 6.8), and were not 
affected by previous therapies: the ORR was 54% among patients refractory to lenalidomide 
only and 71% in patients refractory to both lenalidomide and bortezomib, with equal VGPR 
rate (19%). 
After a median follow-up of 12.8 months, median PFS was 10.3 months, whereas median OS 
was not reached and the 1-year OS was 67% (Figure 1).  
Patients with standard-risk fluorescence in situ hybridization (FISH) had a significantly 
higher ORR rate in comparison with those with high-risk fluorescence in situ hybridization 
(80% vs 40%, respectively; p= 0.04). However, median PFS (11.4 vs 10.7 months, HR 0.61; 
p=0.3) and OS (median not reached in both groups; 1 year-OS: 74% vs 60%, HR 0.54, p=0.3) 
were similar in the two risk groups. 
Similar outcomes were reported in patients refractory to lenalidomide or lenalidomide and 
bortezomib (median PFS: 9.8 vs 10.3 months, HR: 1.16, p=0.68. 
Any grade haematological treatment-emergent adverse events (AEs) occurred in 37 (79%) 
patients, grade 3-4 haematological AEs occurred in 30 (64%) patients, including neutropenia 
in 30 (64%), thrombocytopenia in 6 (13%) and anaemia in 5 (11%) patients (Table 1).  
Any grade non-haematological treatment-emergent AEs were observed in 36 (77%) patients, 
grade 3-4 non-haematological AEs were reported in 11 (23%) patients, and the most frequent 
were infections in 5 (11%), vascular events in 4 (9%), cardiac events and fatigue in 2 (4%) 
patients each; no grade 5 AE was reported.  
Any grade cardiovascular AEs occurred in 9 patients (19%), grade 3-4 events occurred in 5 
(11%) patients, including cardiac AEs in 2 (4%) and hypertension in 3 (6%) patients. 
Nine (19%) patients needed at least one dose reduction due to AEs: 1 (2%) reduced both 
carfilzomib and dexamethasone doses due to dyspnea, 4 (9%) reduced pomalidomide dose (2 
for fever, 1 for pneumonia and 1 for thrombocytopenia) and 4 (9%) reduced dexamethasone 
dose (1 for infection, 1 hypertension, 1 steroid-related myopathy and 1 for hepatic toxicity).  
In patients treated at the MTD of carfilzomib (27 mg/m2), wKPd proved to be safe and 
effective, inducing an objective response in 62% of patients, that translated into a median PFS 
of 10.3 months. Of note, wKPd was active in double refractory patients, with comparable ORR 
(54% vs 71%) and median PFS (10 months in both groups) to patients refractory to 
lenalidomide only.  
Despite the limitations of cross-trial comparisons, wKPd in our study induced higher ORR 
(62% vs 20-30%) and longer PFS (median, 10 vs 4-5 months) compared with pomalidomide 
or carfilzomib plus dexamethasone (2,3,10,11).  
Furthermore, the ORR and median PFS reported with wKPd in our study were not inferior to 
those observed with twice-weekly KPd (ORR 50%; PFS 7 months), with a lower rate of dose 
reductions (19% vs 37%) and treatment discontinuations (4% vs 19%) due to AEs (8). Yet, 
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caution is needed when interpreting these data, as patients enrolled in the above-mentioned 
trials were more heavily pre-treated than patients in our trial.  
In our study, the protocol did not allow investigators to re-escalate the dose of carfilzomib in 
the phase 1; we do not know whether the new safety cardio-vascular procedures might have 
allowed an additional carfilzomib dose escalation to improve the efficacy of the regimen.  
Once-weekly KPd was well tolerated in the present trial: myelosuppression was the major 
toxicity reported but AEs were mainly limited to grade 1-2.  
During the dose escalation phase, 5 DLTs were observed, all cardio-vascular in nature and 
mainly related to hypertension. The adoption of safety procedures, during screening and 
treatment, together with a lower dose of carfilzomib (27 mg/m2), led to a significant 
reduction of any grade (78% vs 19%; p=0.001) and grade 3-4 (56% vs 6%; p=0.003) 
cardiovascular AEs. 
The rates of any grade and grade 3-4 hypertension (6%) and cardiac events (4%) in patients 
treated at the MTD of carfilzomib were consistent with previously published data (4,7,12). 
In conclusion, once-weekly carfilzomib at the MTD of 27 mg/m2, pomalidomide (4 mg) and 
dexamethasone (20 mg) is a safe and effective treatment option for RRMM patients after 
lenalidomide and bortezomib. A baseline screening for cardiovascular risk factors and blood 
pressure monitoring are recommended to guarantee treatment tolerability and compliance. 
The promising ORR and PFS support further investigation of higher doses of once-weekly 
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Figure 1. Time-to-event analysis.  
PFS (A) and OS (B) in patients treated with wKPd at the MTD 
